keliximab

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1998-2002
012319982002

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2003
2003
OBJECTIVE Keliximab studies have provided evidence of the therapeutic potential of a non-depleting CD4 monoclonal antibody (mAb… (More)
Is this relevant?
2002
2002
OBJECTIVE Double blind studies were conducted with the anti-CD4 monoclonal antibody (Mab) keliximab in patients with active… (More)
Is this relevant?
2001
2001
CD4+ T-cells are likely to be involved as a source of pro-inflammatory cytokines in asthma. This study assessed the effects of an… (More)
  • table 1
  • figure 1
  • figure 3
  • figure 2
  • table 2
Is this relevant?
2001
2001
Anti-CD4 antibodies, which cause CD4(+) T-cell depletion, have been shown to increase susceptibility to infections in mice. Thus… (More)
Is this relevant?
2001
2001
Keliximab, a Primatized IgG1 CD4 mAb, was reconfigured to an IgG4 antibody. The gamma4 constant region was further modified by… (More)
Is this relevant?
2001
2001
Studies describing the induction of apoptosis for CD4 mAbs do not delineate between epitope-dependent and Fc-driven epitope cross… (More)
Is this relevant?
2000
2000
The preclinical safety assessment of biopharmaceuticals necessitates that studies be conducted in species in which the products… (More)
Is this relevant?
2000
2000
Keliximab and clenoliximab are monkey/human chimeric CD4 monoclonal antibodies (mAbs) of the IgG1 and IgG4 isotypes, respectively… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Is this relevant?
2000
2000
Several CD4 mAbs have entered the clinic for the treatment of autoimmune diseases or transplant rejection. Most of these mAbs… (More)
  • figure 1
  • figure 2
  • figure 3
  • table I
  • figure 4
Is this relevant?
1998
1998
BACKGROUND There is substantial circumstantial evidence that CD4 lymphocytes have a role in the pathogenesis of chronic asthma… (More)
Is this relevant?